参考文献/References:
[1] Authors/Task Force membersElliott PM,Anastasakis A,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J,2014,35(39):2733-2779.
[2] 中华医学会心血管病学分会中国成人HCM诊断治疗指南编写组中华心血管病杂志编辑委员会. 中国成人HCM诊断治疗指南[J]. 中华心血管病杂志2017,45(12):1015-1032.
[3] BROCK R. Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis[J]. Guys Hosp Rep,1957,106(4):221-238.
[4] Pelliccia F,Pasceri V,Limongelli G,et al. Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy:A systematic review and meta-analysis[J]. Int J Cardiol,2017,243:379-384.
[5] Braunwald E,Ebert PA. Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs[J]. Am J Cardiol,1962,10:489-495.
[6] Maron BJ,Maron MS,Wigle ED,et al. The 50-year history,controversy,and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy:from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2009,54(3):191-200.
[7] Adams JC,Ommen SR,Klarich KW,et al. Significance of postprandial symptom exacerbation in hypertrophic cardiomyopathy[J]. Am J Cardiol,2010,105(7):990-992.
[8] Maron MS,Olivotto I,Zenovich AG,et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction[J]. Circulation,2006,114(21):2232-2239.
[9] Rowin EJ,Maron BJ,Olivotto I,et al. Role of exercise testing in hypertrophic?cardiomyopathy[J]. JACC Cardiovasc Imaging,2017,10(11):1374-1386.
[10] La Canna G,Scarfò I,Arendar I,et al. Phenotyping left ventricular obstruction with postprandial re-test echocardiography in hypertrophic cardiomyopathy[J]. Am J Cardiol,2020,125(11):1688-1693.
[11] 中华医学会超声医学分会超声心动图学组. 负荷超声心动图规范化操作指南[J]. 中国医学影像技术2017,33(4):632-638.
[12] Sigurdsson M,McCartney SL,Maslow A. dynamic left ventricular outflow obstruction and systolic anterior motion of the mitral valve complicating surgical aortic valve replacement[J]. J Cardiothorac Vasc Anesth,2019,33(3):863-865.
[13] Sherrid MV,Gunsburg DZ,Moldenhauer S,et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2000,36(4):1344-1354.
[14] Richard R,Halpern D,Sahn DJ,et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve[J]. J Am Coll Cardiol,2014,64(19):1984-1995.
[15] Melacini P,Basso C,Angelini A,et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy[J]. Eur Heart J,2010,31(17):2111-2123.
[16] Maron BJ. Hypertrophic cardiomyopathy:a systematic review[J]. JAMA,2002,287(10):1308-1320.
[17] Heitner SB,Fischer KL. Lifestyle modification and medical management of hypertrophic cardiomyopathy[J]. Cardiol Clin,2019,37(1):45-54.
[18] Saberi S,Wheeler M,Bragg-Gresham J,et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy:a randomized clinical trial[J]. JAMA,2017,317(13):1349-1357.
[19] Antal A,Boyac?o?lu K,Akbulut M,et al. Surgical management of hypertrophic obstructive cardiomyopathy[J]. Gen Thorac Cardiovasc Surg,2020,68(9):962-968.
[20] Anita N,Schaff HV,Nishimura RA,et al. Survival after myectomy for obstructive hypertrophic cardiomyopathy:what causes late mortality[J]. Ann Thorac Surg,2019,108(3):723-729.
[21] Yu SN,Nakanishi K,Ginns JN,et al. Importance of surgical expertise in septal myectomy for obstructive hypertrophic cardiomyopathy[J]. Gen Thorac Cardiovasc Surg,2020,68(10):1094-1100.
[22] Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J]. Lancet,1995,346(8969):211-214.
[23] Liebregts M,Faber L,Jensen MK,et al. Outcomes of alcohol septal ablation in?younger?patients with obstructive hypertrophic?cardiomyopathy[J]. JACC Cardiovasc Interv,2017,10(11):1134-1143.
[24] Jahnlová D,Toma?ov P,Adlová R,et al. Outcome of patients ≥60 years of age after alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J]. Arch Med Sci,2019,15(3):650-655.
[25] Osman M,Kheiri B,Osman K,et al. Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy:Systematic review and meta-analysis[J]. Clin Cardiol,2019,42(1):190-197.
[26] Sorajja P,Valeti U,Nishimura RA,et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy[J]. Circulation,2008,118(2):131-139.
[27] Liebregts M,Vriesendorp PA,Ten Berg JM. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy:a word of?endorsement[J]. J Am Coll Cardiol,2017,70(4):481-488.
[28] Veselka J,Faber L,Jensen MK,et al. Effect of Institutional experience on outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J]. Can J Cardiol,2018,34(1):16-22.
[29] Armistead SH,Williams BT. Hypertrophic obstructive cardiomyopathy. The use of a diathermy loop for septal resection[J]. J Cardiovasc Surg (Torino),1984,25(2):185-186.
[30] Sreeram N,Emmel M,de Giovanni JV. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children[J]. J Am Coll Cardiol,2011,58(24):2501-2510.
[31] 刘丽文左蕾周梦垚等. 经胸超声心动图引导下经皮心肌内室间隔射频消融术治疗梗阻性HCM的安全性和有效性[J]. 中华心血管病杂志2019,47(4):284-290.
[32] Yang H,Yang Y,Xue Y,et al. Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy:A systematic review and meta-analysis[J]. Clin Cardiol,2020,43(5):450-458.
[33] Liu Q,Li D,Berger AE,et al. Survival and prognostic factors in hypertrophic cardiomyopathy:a meta-analysis[J]. Sci Rep,2017,7(1):11957.
[34] Maron MS,Olivotto I,Betocchi S,et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy[J]. N Engl J Med,2003,348(4):295-303.
[35] Finocchiaro G,Haddad F,Pavlovic A,et al. Latent obstruction and left atrial size are predictors of clinical deterioration leading to septal reduction in hypertrophic cardiomyopathy[J]. J Card Fail, 2014,20(4):236-243.
[36] Lu DY,Pozios I,Haileselassie B,et al. Clinical outcomes in patients with nonobstructive,labile,and obstructive hypertrophic cardiomyopathy[J]. J Am Heart Assoc,2018,7(5):e006657.
[37] Pozios I,Corona-Villalobos C,Sorensen LL,et al. Comparison of outcomes in patients with nonobstructive,labile-obstructive,and chronically obstructive hypertrophic cardiomyopathy[J]. Am J Cardiol,2015,116(6):938-944.
相似文献/References:
[1]王皎.室性期前收缩性心肌病诊疗进展[J].心血管病学进展,2020,(6):563.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.001]
WANG Jiao.Diagnosis and Treatment of Premature Ventricular Contraction-induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(6):563.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.001]
[2]谭莹 易龙 谢峻 徐标 陆剑嵘.一个家族肥厚心肌病的遗传学分析[J].心血管病学进展,2020,(8):880.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.023]
TAN Ying,YI Long,XIE Jun,et al.Genetic Analysis of A Familial Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(6):880.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.023]
[3]刘玉辉 王盼盼 陈椿.心房颤动性心肌病临床研究进展[J].心血管病学进展,2020,(12):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
LIU Yuhui,WANG Panpan,CHEN Chun.Atrial Fibrillation-induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(6):1238.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.004]
[4]王前程 刘伟涛 周忠江.提高对甲状腺素转运蛋白淀粉样变性心肌病诊治的认识[J].心血管病学进展,2021,(3):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
WANG Qiancheng,LIU Weitao,ZHOU Zhongjiang.To Improve the Recognition of Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(6):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
[5]杭成文 崔鸣.Myomesin基因家族及其相关疾病的研究进展[J].心血管病学进展,2021,(4):314.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.007]
HANG Chengwen,CUI Ming.Myomesin Gene Family and Related Diseases[J].Advances in Cardiovascular Diseases,2021,(6):314.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.007]
[6]徐尧 蔡衡 李洪仕.心房颤动合并心力衰竭的导管消融治疗[J].心血管病学进展,2021,(4):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
XU Yao,CAI Heng,LI Hongshi.Role of Radiofrequency Ablation in Patients with Atrial Fibrillation and Heart Failure[J].Advances in Cardiovascular Diseases,2021,(6):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
[7]周小龙 赵晓莹 赵新湘.射血分数正常的肥厚型心肌病患者心肌T1值和T2值研究[J].心血管病学进展,2021,(9):845.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
ZHOU XiaolongZHAO Xiaoying,ZHAO Xinxiang.Study of T1 and T2 Values in Myocardium of Hypertrophic Cardiomyopathy with Normal Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(6):845.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[8]黄勇淇 田龙海 杨龙.室性期前收缩心肌病[J].心血管病学进展,2022,(4):348.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.015]
HUANG Yongqi,TIAN Longhai,YANG Long.Premature Ventricular Complexes Induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(6):348.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.015]
[9]王帅兵 刘江文 黄从新.神经氨酸酶1在心血管疾病中的研究进展[J].心血管病学进展,2023,(11):982.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.006]
WANG Shuaibing,LIU Jiangwen,HUANG Congxin.NEU1 in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2023,(6):982.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.006]
[10]张昕彤 任卫东.心肌病的再认识——从遗传学出发的探索[J].心血管病学进展,2024,(11):961.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.001]
REN Weidong,ZHANG Xintong.A New Recognition on CardiomyopathyIn-Depth Exploration of Genetics[J].Advances in Cardiovascular Diseases,2024,(6):961.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.001]